Mitochondrial-targeting compounds, drugs that increase autophagy, and antioxidants are being trialed in combination therapy to ultimately treat SOD1-ALS, consistently addressing protein aggregation, energy deficits, and oxidative stress together. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.